Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Piper Sandler Maintains Neutral on Travere Therapeutics, Raises Price Target to $12

Author: Benzinga Newsdesk | August 02, 2024 09:55am
Piper Sandler analyst Allison Bratzel maintains Travere Therapeutics (NASDAQ:TVTX) with a Neutral and raises the price target from $11 to $12.

Posted In: TVTX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist